Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus TOLTERODINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus TOLTERODINE TARTRATE.
DETROL LA vs TOLTERODINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5) with relative selectivity for the bladder over salivary glands. Reduces detrusor muscle contractility and bladder pressure.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
2 mg orally twice daily. May be reduced to 1 mg orally twice daily based on tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life is 2-3 hours in extensive metabolizers (CYP2D6) and approximately 9 hours in poor metabolizers. In clinical context, dosing interval is adjusted in poor metabolizers (e.g., 2 mg twice daily reduced to 2 mg once daily).
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Renal (77%) and fecal (17%): approximately 14% as unchanged tolterodine, 51% as the active 5-hydroxymethyl metabolite, and 12% as other metabolites. Biliary excretion contributes minimally.
Category C
Category A/B
Anticholinergic
Anticholinergic